(NASDAQ:NVAX) shareholders might be concerned after seeing the share price drop 15% in the last quarter. But that scarcely detracts from the really solid long term returns generated by the company ...

Novavax shares fell 11.2% during Wednesday's session. Vaccine stocks are volatile after the first US bird flu death and a CDC ...

Novavax (NVAX) and other vaccine developers rise as Investors react to rising flu and COVID-19 cases in the U.S. Read more ...

Moderna leads vaccine rally amid rising respiratory infections, spurring investment in COVID-19, flu, and RSV solutions.

The stock's fall snapped a five-day winning streak.

Investors are weighing Nvidia's big AI plans and puzzling over Trump's tariff policy in the wait for fresh jobs data.

Novavax shares are trading higher by 12.4% during Tuesday's session. A recent CDC report highlights a sharp increase in ...

Novavax NVAX announced that it has started dosing participants in the phase III study evaluating its experimental COVID-19-influenza combination (CIC) and stand-alone influenza vaccine candidates.

Shares of vaccine makers including Moderna, Novavax and CureVac rose Tuesday after U.S. health officials confirmed the first ...

But the company trimmed its outlook. Is NVAX stock a sell in December 2024? Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...

Novavax (NVAX) announced progress in Q4 advancing its corporate growth strategy through its partnership with Sanofi (SNY). The company has achieved a milestone associated with its Phase 2/3 ...

But the company trimmed its outlook. Is NVAX stock a sell in December 2024? Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant ...